» Articles » PMID: 33628590

VEGFR2 Inhibition Hampers Breast Cancer Cell Proliferation Enhanced Mitochondrial Biogenesis

Overview
Journal Cancer Biol Med
Specialty Oncology
Date 2021 Feb 25
PMID 33628590
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Vascular endothelial growth factor (VEGF), apart from its predominant roles in angiogenesis, can enhance cancer cell proliferation, but its mechanisms remain elusive. The purpose of the present study was therefore to identify how VEGF regulates cancer cell proliferation.

Methods: VEGF effects on cancer cell proliferation were investigated with the VEGF receptor 2 inhibitor, Ki8751, and the breast cancer cell lines, MCF-7 and MDA-MB-231, using flow cytometry, mass spectrometry, immunoblotting, and confocal microscopy. Data were analyzed using one-way analysis of variance followed by Tukey's multiple comparison test.

Results: VEGF blockade by Ki8751 significantly reduced cancer cell proliferation, and enhanced breast cancer cell apoptosis. Mass spectrometric analyses revealed that Ki8751 treatment significantly upregulated the expression of mitochondrial proteins, suggesting the involvement of mitochondrial biogenesis. Confocal microscopy and flow cytometric analyses showed that Ki8751 treatment robustly increased the mitochondrial masses of both cancer cells, induced endomitosis, and arrested cancer cells in the high aneuploid phase. VEGFR2 knockdown by shRNAs showed similar effects to those of Ki8751, confirming the specificity of Ki8751 treatment. Enhanced mitochondrial biogenesis increased mitochondrial oxidative phosphorylation and stimulated reactive oxygen species (ROS) production, which induced cancer cell apoptosis. Furthermore, Ki8751 treatment downregulated the phosphorylation of Akt and PGC1α, and translocated PGC1α into the nucleus. The PGC1α alterations increased mitochondrial transcription factor A (TFAM) expression and subsequently increased mitochondrial biogenesis.

Conclusions: VEGF enhances cancer cell proliferation by decreasing Akt-PGC1α-TFAM signaling-mediated mitochondrial biogenesis, ROS production, and cell apoptosis. These findings suggested the anticancer potential of Ki8751 increased mitochondrial biogenesis and ROS production.

Citing Articles

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.


From metabolism to malignancy: the multifaceted role of PGC1α in cancer.

Wang Y, Peng J, Yang D, Xing Z, Jiang B, Ding X Front Oncol. 2024; 14:1383809.

PMID: 38774408 PMC: 11106418. DOI: 10.3389/fonc.2024.1383809.


VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.

Guo M, Zhang J, Han J, Hu Y, Ni H, Yuan J J Transl Med. 2024; 22(1):419.

PMID: 38702818 PMC: 11067099. DOI: 10.1186/s12967-024-05155-1.


Development of a cancer metastasis-on-chip assay for high throughput drug screening.

Ozer L, Fayed H, Ericsson J, Al Haj Zen A Front Oncol. 2024; 13:1269376.

PMID: 38239643 PMC: 10794518. DOI: 10.3389/fonc.2023.1269376.


(E)-2-Methoxy-4-(3-(4-Methoxyphenyl) Prop-1-en-1-yl) Phenol Suppresses Breast Cancer Progression by Dual-Regulating VEGFR2 and PPARγ.

Kim N, Park H, Lee H, Hong J, Yoon D J Microbiol Biotechnol. 2023; 34(2):240-248.

PMID: 37942548 PMC: 10940741. DOI: 10.4014/jmb.2309.09019.


References
1.
Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

2.
Laws K, Bineva-Todd G, Eskandari A, Lu C, OReilly N, Suntharalingam K . A Copper(II) Phenanthroline Metallopeptide That Targets and Disrupts Mitochondrial Function in Breast Cancer Stem Cells. Angew Chem Int Ed Engl. 2017; 57(1):287-291. DOI: 10.1002/anie.201710910. View

3.
Li N . Platelets in cancer metastasis: To help the "villain" to do evil. Int J Cancer. 2015; 138(9):2078-87. DOI: 10.1002/ijc.29847. View

4.
Chen J . miRNA‑195 suppresses cell proliferation of ovarian cancer cell by regulating VEGFR2 and AKT signaling pathways. Mol Med Rep. 2018; 18(2):1666-1673. DOI: 10.3892/mmr.2018.9098. View

5.
Chae Y, Vaira V, Caino M, Tang H, Seo J, Kossenkov A . Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell. 2016; 30(2):257-272. PMC: 5131882. DOI: 10.1016/j.ccell.2016.07.004. View